NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.
NOC4L shows promise as a dual-action target, functioning both as a prognostic biomarker and as a potential immunotherapeutic target, and is associated with overall survival in 20 cancer types, suggesting its potential as an independent prognostic marker.